secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001104659-23-099482
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics aligns with FDA on Phase 2/3 registrational trial for BT8009 in metastatic bladder cancer
--------------------------------------------------------------------------------

- FDA alignment reached on Duravelo-2 trial design; trial to begin Q1 2024.
- Potential accelerated approval based on ORR, with PFS to confirm benefit.
- Cohort 1: BT8009 + pembrolizumab in untreated metastatic bladder cancer.
- Cohort 2: BT8009 monotherapy and combo in previously treated patients.
- Discussions ongoing for confirmatory trial design in second-line-plus setting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923099482/0001104659-23-099482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465923099482/tm2325810d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer